Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Anlotinib combined Docetaxel
DRUG
2 trials
Sponsors
Yong Fang
, China Medical University, China
Conditions
Non-small Cell Lung Cancer
Phase 1
Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC
NCT03726736
Yong Fang
Non-small Cell Lung Cancer
Start: 2018-12-21
End: 2020-11-01
Target: 97
Updated: 2019-06-07
Phase 2
A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC
NCT03732001
China Medical University, China
Non-small Cell Lung Cancer
Start: 2018-11-08
End: 2020-11-09
Target: 80
Updated: 2018-11-28
Related Papers
Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial
Cancer
2025-05-14
1 citations
Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials.
2025-05-12
Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.
Journal of Clinical Oncology
2024-06-01
1 citations
Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.
Journal of Clinical Oncology
2021-05-20
3 citations